Detalles de la búsqueda
1.
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
J Viral Hepat
; 29(12): 1050-1061, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36036117
2.
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
J Hepatol
; 72(3): 431-440, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655134
3.
HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America.
Ann Hepatol
; 19(2): 161-165, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31718995
4.
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Liver Int
; 38(9): 1571-1575, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29377566
5.
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
J Hepatol
; 67(4): 700-707, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28645740
6.
Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
Liver Int
; 37(1): 5-18, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27473533
7.
A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
Liver Int
; 34(10): 1550-9, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24329937
8.
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
Liver Int
; 34(7): e217-28, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24251988
9.
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Hepatology
; 56(6): 2039-50, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22706730
10.
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
J Clin Gastroenterol
; 47(9): 786-93, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23442834
11.
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
J Clin Gastroenterol
; 47(3): 271-9, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22951527
12.
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
J Hepatol
; 56(6): 1276-82, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22314423
13.
Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.
Liver Int
; 37(11): 1743-1744, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28853201
14.
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Liver Int
; 32(8): 1270-7, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22621707
15.
Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Ann Hepatol
; 11(1): 52-61, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22166561
16.
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Adv Ther
; 38(6): 3409-3426, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34021887
17.
[Hemoglobin levels in hemodialysis patients treated with epoetin: a Brazilian experience]. / Variação dos níveis de hemoglobina de pacientes em hemodiálise tratados com eritropoetina: uma experiência brasileira.
Rev Assoc Med Bras (1992)
; 56(2): 209-13, 2010.
Artículo
en Portugués
| MEDLINE | ID: mdl-20498997
18.
SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
Ann Hepatol
; 13(2): 303-4, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24558225
19.
Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study.
Clin Neuropharmacol
; 29(3): 138-43, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16772812
20.
Pharmacoeconomics applied to chronic hepatitis C.
Braz J Infect Dis
; 10(1): 51-4, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16767316